Biological signature characteristics of primary isolates from human immunodeficiency virus type 1 group O in ex vivo human tonsil histocultures.
Human immunodeficiency virus type 1 (HIV-1) group M viruses have achieved a global distribution, while HIV-1 group O viruses are endemic only in particular regions of Africa. Here, we evaluated biological characteristics of group O and group M viruses in ex vivo models of HIV-1 infection. The replicative capacity and ability to induce CD4 T-cell depletion of eight group O and seven group M primary isolates were monitored in cultures of human peripheral blood mononuclear cells and tonsil explants. Comparative and longitudinal infection studies revealed HIV-1 group-specific activity patterns: CCR5-using (R5) viruses from group M varied considerably in their replicative capacity but showed similar levels of cytopathicity. In contrast, R5 isolates from group O were relatively uniform in their replicative fitness but displayed a high and unprecedented variability in their potential to deplete CD4 T cells. Two R5 group O isolates were identified that cause massive depletion of CD4 T cells, to an extent comparable to CXCR4-using viruses and not documented for any R5 isolate from group M. Intergroup comparisons found a five- to eightfold lower replicative fitness of isolates from group O than for isolates from group M yet a similar overall intrinsic pathogenicity in tonsil cultures. This study establishes biological ex vivo characteristics of HIV-1 group O primary isolates. The current findings challenge the belief that a grossly reduced replicative fitness or inherently impaired cytopathicity of viruses from this group underlies their low global prevalence.
Geuenich
Silvia
S
Department of Virology, University of Heidelberg, Heidelberg, Germany.
Kaderali
Lars
L
Allespach
Ina
I
Sertel
Serkan
S
Keppler
Oliver T
OT
D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D002478:Cells, Cultured; D003588:Cytopathogenic Effect, Viral; D015497:HIV-1 / Q000145:classification* / Q000302:isolation & purification / Q000472:pathogenicity* / Q000502:physiology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology*; D008213:Lymphocyte Activation; D009924:Organ Culture Techniques; D014066:Palatine Tonsil / Q000166:cytology / Q000276:immunology / Q000821:virology*; D019713:Receptors, CCR5 / Q000378:metabolism; D014779:Virus Replication
D019713:Receptors, CCR5
Nat Protoc. 2009;4(2):256-69
19197269
N Engl J Med. 1994 Aug 11;331(6):341-6
8028613
AIDS. 2003 Mar 28;17(5):780-1
12646811
J Virol. 1995 Sep;69(9):5640-9
7637010
Lancet Infect Dis. 2009 Feb;9(2):118-29
19179227
J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Aug 1;12(4):427-8
8673554
J Immunol. 2004 Feb 15;172(4):2687-96
14764744
J Virol Methods. 2003 Oct;113(1):43-9
14500126
J Immunol. 2006 Nov 1;177(9):6227-37
17056552
Virology. 2003 Jun 5;310(2):254-66
12781713
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):432-9
18931623
J Virol. 2002 Jul;76(14):6966-73
12072497
Nat Med. 1995 Dec;1(12):1320-2
7489416
J Virol. 2001 Sep;75(17):8063-73
11483751
J Virol. 2003 May;77(10):5846-54
12719578
J Virol. 1991 Nov;65(11):5782-9
1920616
J Infect Dis. 2002 Aug 15;186(4):486-92
12195375
AIDS Rev. 2007 Apr-Jun;9(2):75-87
17694675
AIDS Res Hum Retroviruses. 1996 Nov 20;12(17):1647-9
8947302
AIDS. 1997 Sep;11(11):1410-2
9302460
J Virol. 2005 Jul;79(14):8979-90
15994792
AIDS. 1993 Nov;7(11):1536-8
8280429
Nat Rev Microbiol. 2007 Feb;5(2):141-51
17203103
J Virol. 2004 Nov;78(22):12689-93
15507658
J Clin Invest. 2008 Oct;118(10):3440-52
18776939
J Immunol. 2006 Mar 1;176(5):2888-95
16493046
Lancet. 1996 Jul 13;348(9020):116
8676681
Proc Natl Acad Sci U S A. 1993 May 1;90(9):4226-30
8483938
J Virol. 2003 Apr;77(7):4389-95
12634395
AIDS Res Hum Retroviruses. 1997 Apr 10;13(6):461-71
9100987
J Virol. 2005 Apr;79(8):5220-6
15795306
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10752-7
10485898
J Virol. 2001 Sep;75(18):8842-7
11507229
Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):663-8
9892690
Immunity. 2001 Oct;15(4):671-82
11672548
Virology. 2005 Mar 15;333(2):251-62
15721359
Science. 2000 Apr 7;288(5463):55-6
10766634
Nat Med. 1999 Mar;5(3):344-6
10086394
Science. 2000 Jun 9;288(5472):1789-96
10846155
J Virol. 2000 Jan;74(1):184-92
10590105
Virology. 2004 Sep 1;326(2):329-39
15321704
J Virol. 1994 Mar;68(3):1581-5
8107219
AIDS. 2007 Nov 12;21(17):2351-3
18090288
Nat Med. 1998 Mar;4(3):346-9
9500611
J Clin Invest. 1999 Sep;104(5):R7-R11
10487781
N Engl J Med. 1997 Apr 10;336(15):1072-8
9091805
J Virol. 2009 Jun;83(11):5592-605
19297481
Emerg Infect Dis. 2001 May-Jun;7(3):466-7
11384531
J Virol. 2005 Feb;79(3):1655-65
15650191
Retrovirology. 2008 Mar 20;5:27
18355409
Retrovirology. 2009 Jan 15;6:6
19146681
J Virol. 2005 Sep;79(17):11179-86
16103169
AIDS Res Hum Retroviruses. 2006 Jan;22(1):83-92
16438650
J Virol. 2000 Oct;74(20):9594-600
11000231
Infection. 1995 Nov-Dec;23(6):369-70
8655208
Virology. 1997 Apr 28;231(1):43-7
9143301